Effect of L-carnitine on mortality in obese patients with coronavirus

Phase 3

Recruiting

Conditions: Acute respiratory infection caused by coronavirus.
Acute upper respiratory infection, unspecified
J06.9

Registration Number: IRCT20220418054581N1

Lead Sponsor: Artesh University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 40

Inclusion Criteria

Patients over 18 years
Diagnosis of clinical and laboratory signs of severe Covid-19
Body mass index above 29.9 kg per square meter based on the weight in the file
Completion of the informed consent form by the patient or his / her legal guardian
Severe COVID-19 patients who are admitted to the medical ICU (MICU) and will require respiratory support
Patients with normal GI function who receive enteral feeding

Exclusion Criteria

Receive any L-carnitine supplement in the last 6 months
Participate in any other research project
History of liver and kidney disease
Pregnancy and lactation
Any allergy to L-carnitine
Patients who stayed in the ICU for < 72 hours
Patients who receive parenteral nutritional support
Patients treated with different drug regimens from the routine ICU protocol
Patients will be ongoing treatment with cisplatin, phenobarbital, phenytoin, pivalic acid, valproic acid, ifosfamide, and levetiracetam
Any gastrointestinal disorders that lead to stopping enteral feeding for more than 48 hours

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
28 days mortality. Timepoint: From the beginning of the intervention up to 28 days. Method of measurement: Record and view the file.;Serum level of acute phase reactive protein C. Timepoint: The beginning of the intervention and day 7. Method of measurement: Biochemically and using the appropriate kit.;Ratio of serum level of acute phase C-reactive protein to albumin. Timepoint: The beginning of the intervention and day 7. Method of measurement: Biochemically and using the appropriate kit.;ICU mortality. Timepoint: from beginning until ICU follow up. Method of measurement: Record and view the file.;The number of ventilator-dependent days. Timepoint: The beginning of the intervention until day 7. Method of measurement: Record and view the file.

Secondary Outcome Measures

Name	Time	Method
ength of stay in the ICU. Timepoint: beginning of intervention until 7 days later. Method of measurement: record and view of files.;Serum levels of neutrophils and lymphocytes. Timepoint: beginning of intervention and 7 days later. Method of measurement: By biochemical methods and related kits.